Cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis

被引:27
|
作者
Rosner, AJ [1 ]
Grima, DT [1 ]
Torrance, GW [1 ]
Bradley, C [1 ]
Adachi, JD [1 ]
Sebaldt, RJ [1 ]
Willison, DJ [1 ]
机构
[1] Innovus Res Inc, Burlington, ON L7L 6B8, Canada
关键词
D O I
10.2165/00019053-199814050-00007
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objective: The aim of this study was to evaluate the cost effectiveness of multitherapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis. Design: A retrospective, incremental cost-effectiveness analysis was conducted from a societal perspective. It compared 9 treatment strategies over 3 years and incorporated the willingness of patients to initiate and continue each therapy. Main outcome measures and results: Four nondominated strategies formed the efficient frontier in the following order: (i) calcium --> no therapy; (ii) ovarian hormone therapy (OHT) --> calcium --> no therapy [166 Canadian dollars ($Can)]; (iii) OHT --> etidronate --> calcium --> no therapy ($Can2331); and (iv) OHT --> alendronate --> calcium --> no therapy ($Can40 965). The figures in parentheses are the incremental costs per vertebral fracture averted to move to that strategy from the previous strategy for patients who had undergone a hysterectomy. Conclusions: We identified 4 efficient multi-therapy strategies for the treatment of vertebral osteoporosis in postmenopausal women, 2 of which were consistent with the practice guidelines of the Osteoporosis Society of Canada. Decisionmakers may select from among these efficient strategies on the basis of incremental cost effectiveness.
引用
收藏
页码:559 / 573
页数:15
相关论文
共 50 条
  • [21] Cost effectiveness analysis of osteoporosis treatment in the prevention of fractures in Singapore
    Lau, TC
    OSTEOPOROSIS INTERNATIONAL, 2003, 14 : S79 - S79
  • [22] Cost effectiveness of alendronate (Fosamax®) for the treatment of osteoporosis and prevention of fractures
    Johnell, O
    Jönsson, B
    Jönsson, L
    Black, D
    PHARMACOECONOMICS, 2003, 21 (05) : 305 - 314
  • [23] Cost Effectiveness of Alendronate (Fosamax®) for the Treatment of Osteoporosis and Prevention of Fractures
    Olof Johnell
    Bengt Jönsson
    Linus Jönsson
    Dennis Black
    PharmacoEconomics, 2003, 21 : 305 - 314
  • [24] DENOSUMAB FOR PREVENTION OF FRACTURES IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS
    Tofilovska, S. T. J.
    Prosheva, T. B. P. Bajraktarova
    Jordanova, S. J.
    OSTEOPOROSIS INTERNATIONAL, 2018, 29 : S457 - S458
  • [25] Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
    Cummings, Steven R.
    San Martin, Javier
    McClung, Michael R.
    Siris, Ethel S.
    Eastell, Richard
    Reid, Ian R.
    Delmas, Pierre
    Zoog, Holly B.
    Austin, Matt
    Wang, Andrea
    Kutilek, Stepan
    Adami, Silvano
    Zanchetta, Jose
    Libanati, Cesar
    Siddhanti, Suresh
    Christiansen, Claus
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (08): : 756 - 765
  • [26] The cost-effectiveness of calcium and vitamin D or hormone replacement therapy in the prevention of osteoporosis and osteoporotic fractures in Canadian postmenopausal women.
    Papadimitropoulos, EA
    Goeree, R
    Blackhouse, G
    Coyte, P
    Josse, RG
    Adachi, J
    Greenwood, C
    JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 : S384 - S384
  • [27] A Cost-Effectiveness Model of Tibolone as Treatment for the Prevention of Osteoporotic Fractures in Postmenopausal Women in Sweden
    Michael Willis
    Knut Ödegaard
    Ulf Persson
    Johan Hedbrant
    Dan Mellström
    Mats Hammar
    Clinical Drug Investigation, 2001, 21 : 115 - 127
  • [28] A cost-effectiveness model of tibolone as treatment for the prevention of osteoporotic fractures in postmenopausal women in Sweden
    Willis, M
    Ödegaard, K
    Persson, U
    Hedbrant, J
    Mellström, D
    Hammar, M
    CLINICAL DRUG INVESTIGATION, 2001, 21 (02) : 115 - 127
  • [29] Modelled cost-effectiveness and cost-utility analysis of various treatment strategies in polish osteoporotic postmenopausal women without previous vertebral fractures
    Orlewska, E
    Lis, J
    OSTEOPOROSIS INTERNATIONAL, 2002, 13 : S46 - S46
  • [30] Prevention and treatment of osteoporosis in postmenopausal women
    French, L
    Smith, M
    Shimp, L
    JOURNAL OF FAMILY PRACTICE, 2002, 51 (10): : 875 - 882